$SIGY
Sigyn Therapeutics, Inc. Stock $sigy

$sigy Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009883 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$335.9K	$330.7K	$1.490M
YoY Change	-11.81%	-738.23%	16.91%
% of Gross Profit
Research & Development	$147.8K	$140.9K	$657.7K
YoY Change	-35.25%	-78.09%	-10.4%
% of Gross Profit
Depreciation & Amortization	$1.715K	$2.610K	$6.854K
YoY Change	-34.04%	1.56%	-64.23%
% of Gross Profit
Operating Expenses	$521.3K	$471.6K	$2.147M
YoY Change	-14.44%	-20.2%	6.92%
Operating Profit	-$521.3K		-$2.147M
YoY Change	-14.44%		6.92%
Interest Expense	-$835.6K	-$387.4K	-$782.6K
YoY Change	1114.33%	286.62%	69.99%
% of Operating Profit
Other Income/Expense, Net	-$819.8K		-$782.6K
YoY Change	1091.36%		-21.46%
Pretax Income	-$1.341M	-$858.9K	-$2.930M
YoY Change	97.78%	-30.01%	-2.49%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.341M	-$858.9K	-$2.930M
YoY Change	97.78%	-30.01%	-2.49%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03		-$0.08
Diluted Earnings Per Share	-$0.03	-$0.02	-$0.08
COMMON SHARES
Basic Shares Outstanding	42.71M shares	37.30M shares	37.40M shares
Diluted Shares Outstanding	38.47M shares		37.40M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$322.3K	$8.360K	$8.360K
YoY Change	296.03%	-97.55%	-97.55%
Cash & Equivalents	$322.3K	$8.356K
Short-Term Investments
Other Short-Term Assets	$40.16K	$11.94K	$11.94K
YoY Change	227.84%	475.52%	474.04%
Inventory	$50.00K	$50.00K	$50.00K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$412.5K	$70.30K	$70.30K
YoY Change	187.19%	-82.11%	-82.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.34K	$22.05K	$239.8K
YoY Change	-92.69%	-21.37%	-17.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.71K	$20.71K	$20.71K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$248.0K	$262.6K	$262.6K
YoY Change	-18.38%	-17.23%	-17.23%
TOTAL ASSETS
Total Short-Term Assets	$412.5K	$70.30K	$70.30K
Total Long-Term Assets	$248.0K	$262.6K	$262.6K
Total Assets	$660.4K	$332.9K	$332.9K
YoY Change	47.62%	-53.13%	-53.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$265.1K	$327.5K	$327.5K
YoY Change	35.14%	721.81%	725.61%
Accrued Expenses	$96.22K	$83.32K	$83.32K
YoY Change	101.34%	76.68%	76.68%
Deferred Revenue
YoY Change
Short-Term Debt	$2.471M	$1.637M	$1.637M
YoY Change	250.55%	152.88%	152.88%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.833M	$2.049M	$2.049M
YoY Change	197.99%	179.03%	179.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$173.0K	$187.4K	$187.4K
YoY Change	-24.15%	-22.11%	-22.11%
Total Long-Term Liabilities	$173.0K	$187.4K	$187.4K
YoY Change	-24.15%	-22.11%	-22.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.833M	$2.049M	$2.049M
Total Long-Term Liabilities	$173.0K	$187.4K	$187.4K
Total Liabilities	$3.006M	$2.236M	$2.236M
YoY Change	155.01%	129.38%	129.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.537M	-$7.196M
YoY Change		68.68%
Common Stock	$4.281K	$3.826K
YoY Change		-99.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.346M	-$1.903M	-$1.903M
YoY Change
Total Liabilities & Shareholders Equity	$660.4K	$332.9K	$332.9K
YoY Change	47.62%	-53.13%	-53.13%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.341M	-$858.9K	-$2.930M
YoY Change	97.78%	-30.01%	-2.49%
Depreciation, Depletion And Amortization	$1.715K	$2.610K	$6.854K
YoY Change	-34.04%	1.56%	-64.23%
Cash From Operating Activities	-$562.6K	-$451.8K	-$1.830M
YoY Change	22.41%	-18.3%	3.16%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$860.00
YoY Change		-100.0%	-102.94%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities		$0.00	-$860.00
YoY Change		-100.0%	-97.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$876.5K	432.0K	$1.499M
YoY Change	338.27%	8.0%	-27.26%
NET CHANGE
Cash From Operating Activities	-$562.6K	-451.8K	-$1.830M
Cash From Investing Activities		0.000	-$860.00
Cash From Financing Activities	$876.5K	432.0K	$1.499M
Net Change In Cash	$314.0K	-19.76K	-$332.6K
YoY Change		-87.8%	-229.64%
FREE CASH FLOW
Cash From Operating Activities	-$562.6K	-$451.8K	-$1.830M
Capital Expenditures		$0.00	$860.00
Free Cash Flow		-$451.8K	-$1.831M
YoY Change		-16.94%	4.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001642159
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Marketing Expense MarketingExpense		usd
CY2022	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets		usd
CY2021	SIGN	Common Stock Issued In Conjunction With Cashless Exercise Of Warrants CommonStockIssuedInConjunctionWithCashlessExerciseOfWarrants		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Increase Decrease In Other Regulatory Assets IncreaseDecreaseInOtherRegulatoryAssets		usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	SIGN	Amortization Of Warrants Issued In Connection With Debt Modification AmortizationOfWarrantsIssuedInConnectionWithDebtModification		usd
CY2021Q4	SIGN	Beneficial Conversion Feature BeneficialConversionFeature		usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2021Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage		pure
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55575
CY2022	dei	Entity Registrant Name EntityRegistrantName	SIGYN THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2573116
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2468 Historic Decatur Road Ste.
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	140
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92106
CY2022	dei	City Area Code CityAreaCode	(619)
CY2022	dei	Local Phone Number LocalPhoneNumber	353-0800
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	2913953	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42713325	shares
CY2022	dei	Auditor Firm AuditorFirmId	6651
CY2022	dei	Auditor Name AuditorName	Kreit & Chiu CPA LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8356	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	340956	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	50000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	50000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11942	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2075	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	70298	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	393031	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22052	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28046	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2100	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5700	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	217718	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	262771	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20711	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20711	usd
CY2022Q4	us-gaap	Assets Assets	332879	usd
CY2021Q4	us-gaap	Assets Assets	710259	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	327517	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	39674	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	30124	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1072	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	642660	usd
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	53614	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1636656	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	647202	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53200	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46091	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1197	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	179	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2048694	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	734218	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	187425	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	240625	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	187425	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	240625	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2236119	usd
CY2021Q4	us-gaap	Liabilities Liabilities	974843	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38263813	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38263813	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37295813	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37295813	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3826	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3730	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5288510	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3997445	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7195576	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4265759	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1903240	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-264584	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	332879	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	710259	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	457	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	657657	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	734014	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1489151	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1274203	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2147265	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2008217	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2147265	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2008217	usd
CY2021	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	536047	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	438	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	30867	usd
CY2022	SIGN	Interest Expense Debt Discount InterestExpenseDebtDiscount	646302	usd
CY2021	SIGN	Interest Expense Debt Discount InterestExpenseDebtDiscount	368205	usd
CY2022	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	135812	usd
CY2021	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	61283	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-782552	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-996402	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2929817	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3004619	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2929817	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3004619	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37396591	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36396594	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	99179	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	249100	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	188069	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	101972	usd
CY2021	SIGN	Common Stock And Warrants Issued For Cash CommonStockAndWarrantsIssuedForCash	1865000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	236715	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3004619	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-264584	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-264584	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	793039	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	273700	usd
CY2022	SIGN	Adjustments To Additional Paid In Capital Amortization Of Warrants Issued In Connection With Debt Modification AdjustmentsToAdditionalPaidInCapitalAmortizationOfWarrantsIssuedInConnectionWithDebtModification	147720	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	145200	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-68498	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2929817	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1903240	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1903240	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2929817	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3004619	usd
CY2022	us-gaap	Depreciation Depreciation	6854	usd
CY2021	us-gaap	Depreciation Depreciation	2946	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	3600	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	16205	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	249100	usd
CY2022	SIGN	Accretion Of Debt Discount AccretionOfDebtDiscount	-646302	usd
CY2021	SIGN	Accretion Of Debt Discount AccretionOfDebtDiscount	-368205	usd
CY2022	SIGN	Accretion Of Original Issuance Costs AccretionOfOriginalIssuanceCosts	135812	usd
CY2021	SIGN	Accretion Of Original Issuance Costs AccretionOfOriginalIssuanceCosts	61283	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	30800	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	536047	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	9867	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2075	usd
CY2021	us-gaap	Increase Decrease In Other Regulatory Assets IncreaseDecreaseInOtherRegulatoryAssets	20711	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	287843	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23669	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	29052	usd
CY2021	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-58635	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-21	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	23603	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1830242	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1774182	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	860	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29264	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-860	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29264	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1567000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	250000	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	55000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1865000	usd
CY2022	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	68498	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1498502	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2060000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-332600	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	256554	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	340956	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	84402	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8356	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	340956	usd
CY2022	SIGN	Beneficial Conversion Feature In Conjunction With Debt Issuance BeneficialConversionFeatureInConjunctionWithDebtIssuance	273700	usd
CY2021	SIGN	Beneficial Conversion Feature In Conjunction With Debt Issuance BeneficialConversionFeatureInConjunctionWithDebtIssuance	101972	usd
CY2022	SIGN	Amortization Of Warrants Issued In Connection With Debt Modification AmortizationOfWarrantsIssuedInConnectionWithDebtModification	147720	usd
CY2022	SIGN	Warrants Issued To Third Parties In Conjunction With Debt Issuance WarrantsIssuedToThirdPartiesInConjunctionWithDebtIssuance	793039	usd
CY2021	SIGN	Warrants Issued To Third Parties In Conjunction With Debt Issuance WarrantsIssuedToThirdPartiesInConjunctionWithDebtIssuance	188069	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	156700	usd
CY2021	us-gaap	Notes Issued1 NotesIssued1	126030	usd
CY2022	SIGN	Common Stock Issued To Third Parties In Conjunction With Exchange Of Debt CommonStockIssuedToThirdPartiesInConjunctionWithExchangeOfDebt	145104	usd
CY2021	SIGN	Common Stock Issued To Third Parties In Conjunction With Exchange Of Debt CommonStockIssuedToThirdPartiesInConjunctionWithExchangeOfDebt	236715	usd
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42713325	shares
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_800_eus-gaap--BasisOfAccounting_zUgmj7qERHXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82A_zD6CYbHVGrLd">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include all adjustments necessary for the fair presentation of the Company’s financial position and results of operations for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of businesses or separate business entities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zz3raWACzOHc" title="Accumulated deficit">7,195,576</span> at December 31, 2022, had a working capital deficit of approximately $<span id="xdx_908_ecustom--WorkingCapitalDeficit_iI_c20221231_zyzr4cEQm3Ti" title="Working capital">1,978,396</span> at December 31, 2022, had net losses of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zA71giUd5yFe" title="Net loss">2,929,817</span> and $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20210101__20211231_zHzjqhrO0741" title="Net loss">3,004,619</span> for the years ended December 31, 2022 and 2021, respectively, and net cash used in operating activities of $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20220101__20221231_zNVmY81VO1Bh" title="Net cash provided by used in operating activities">1,830,242</span> and $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20210101__20211231_zfMJfEmn1Ms3" title="Net cash provided by used in operating activities">1,774,182</span> for the years ended December 31, 2022 and 2021, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7195576	usd
CY2022Q4	SIGN	Working Capital Deficit WorkingCapitalDeficit	1978396	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2929817	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3004619	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1830242	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1774182	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zKIb28e802Ec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zfR77nh0evw7">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others: common stock valuation, and the recoverability of intangibles. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	536047	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5099	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2100	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5700	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	457	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	657657	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	734014	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	50000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8699	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKVmyO7QoMQl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z9oVe74hycof">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: #F9F9F9">An adjustment has been made to the Consolidated Balance Sheets as of December 31, 2021, to reclass $<span id="xdx_902_eus-gaap--OtherLiabilitiesCurrent_iI_c20211231__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_z4XG2KiKvIYa" title="Other current liabilities">1,072</span> of other current liabilities previously classified in accrued payroll and payroll taxes. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zeBXAh5z4H4h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z4tYiLOLVHKc">Concentrations, Risks, and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Business Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial business risks and uncertainties are inherent to an entity, including the potential risk of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general economic conditions, price of components, competition, and governmental and political conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest rate risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets and liabilities do not have material interest rate risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Credit risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are recognized financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Seasonality</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business is not subject to substantial seasonal fluctuations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Major Suppliers</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sigyn Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on third-party organizations to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement of Sigyn Therapy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10146	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3292	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22052	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28046	usd
CY2022	us-gaap	Depreciation Depreciation	6854	usd
CY2021	us-gaap	Depreciation Depreciation	2946	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10799	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10799	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2100	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2100	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3600	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16205	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2279316	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	700816	usd
CY2022Q4	SIGN	Debt Instrument Original Discount DebtInstrumentOriginalDiscount	-74502	usd
CY2021Q4	SIGN	Debt Instrument Original Discount DebtInstrumentOriginalDiscount	-53614	usd
CY2022Q4	SIGN	Beneficial Conversion Feature BeneficialConversionFeature	-175275	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	392883	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1636656	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	647202	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2279316	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	2279316	usd
CY2020Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	616500	usd
CY2021	SIGN	Extension Of Convertible Note Payable ExtensionOfConvertibleNotePayable	101030	usd
CY2021	SIGN	Exchange Of Convertible Note Payable For Common Stock ExchangeOfConvertibleNotePayableForCommonStock	16714	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	700816	usd
CY2022	SIGN	Convertible Notes Payable Issued ConvertibleNotesPayableIssued	1578500	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2279316	usd
CY2020Q4	SIGN	Debt Instrument Note Discounts DebtInstrumentNoteDiscounts	97832	usd
CY2021	SIGN	Note Discounts In Conjunction With Extension Of Convertible Note NoteDiscountsInConjunctionWithExtensionOfConvertibleNote	65230	usd
CY2021	SIGN	Accretion Of Note Discounts AccretionOfNoteDiscounts	109448	usd
CY2021Q4	SIGN	Debt Instrument Note Discounts DebtInstrumentNoteDiscounts	53614	usd
CY2022	SIGN	Note Discounts Issued In Conjunction With Debt NoteDiscountsIssuedInConjunctionWithDebt	1015039	usd
CY2022	SIGN	Accretion Of Note Discounts AccretionOfNoteDiscounts	425993	usd
CY2022	SIGN	Accretion Of Note Discounts AccretionOfNoteDiscounts	425993	usd
CY2022Q4	SIGN	Debt Instrument Note Discounts DebtInstrumentNoteDiscounts	592660	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	647202	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1636656	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.19	pure
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38263813	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38263813	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37295813	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37295813	shares
CY2021Q2	us-gaap	Payments For Rent PaymentsForRent	5955	usd
CY2021Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-09-30
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	71676	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	41811	usd
CY2022	us-gaap	Lease Cost LeaseCost	71676	usd
CY2021	us-gaap	Lease Cost LeaseCost	41811	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	72714	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	17866	usd
CY2022	SIGN	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	72714	usd
CY2021	SIGN	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	17866	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M1D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	74895	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	77142	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	79456	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	54225	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	285718	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2022Q4	SIGN	Lease Liability Present Values LeaseLiabilityPresentValues	240625	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53200	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	187425	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	240625	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	45093	usd
CY2022	us-gaap	Lease Cost LeaseCost	71676	usd
CY2021	us-gaap	Lease Cost LeaseCost	41811	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1408000	usd
CY2021Q4	SIGN	Net Operating Loss Carryforward Limitation Percentage NetOperatingLossCarryforwardLimitationPercentage	0.80	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.075	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.040	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.205	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.240	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1674531	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1073527	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1674531	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1073527	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26919433	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13482498	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2929817	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3004619	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37396591	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36396594	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37396591	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36396594	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08

Files In Submission

Name	View Source	Status
0001493152-23-009883-index-headers.html	Edgar Link	pending
0001493152-23-009883-index.html	Edgar Link	pending
0001493152-23-009883.txt	Edgar Link	pending
0001493152-23-009883-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sign-20221231.xsd	Edgar Link	pending
sign-20221231_cal.xml	Edgar Link	unprocessable
sign-20221231_pre.xml	Edgar Link	unprocessable
sign-20221231_def.xml	Edgar Link	unprocessable
sign-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIGY
Sigyn Therapeutics, Inc. Stock $sigy

2023 Q1 Form 10-K Financial Statement

#000149315223009883 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIGY Sigyn Therapeutics, Inc. Stock $sigy

2023 Q1 Form 10-K Financial Statement

#000149315223009883 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIGY
Sigyn Therapeutics, Inc. Stock $sigy